Valeant Pharmaceuticals International, Inc. (NYSE:VRX)'s central and eastern European assets have attracted interest from potential private equity bidders and could fetch more than $1 billion. Multiple media outlets cited a Bloomberg report that said Cvc Capital Partners Sicav-Fis S.A., Advent International Corporation and other drug makers would look at the assets if they were put up for sale although there has been no formal sale process. Valeant is up more than 3% in afternoon trading.